Design and Evaluation of Voriconazole Eye Drops for the Treatment of Fungal Keratitis

Table 3

Effect of different viscosity modifiers on the in vitro transcorneal permeation of voriconazole from ophthalmic solution through freshly excised goat cornea.

Formulations	Viscosity (cp) at 100 rpm	Amount of drug permeated in 120 mins	% in vitro permeation	𝑃app  × 10^−6 (cm/s)	Corneal hydration
None	0.98	0.317±0.001^††	2.12±0.003^††	30.72±0.055^††	77.88±0.15
PVA 1.4%	05.43	0.287±0.001^††	1.918±0.003^††	26.91±0.051^††	77.63±1.40
CS 2%	15.23	0.256±0.001^††	1.71±0.003^††	23.99±0.050^††	77.71±1.48
GG 1.5%	62.66	0.192±0.001^††	1.281±0.003^††	17.97±0.050^††	79.36±0.35
SA 2%	132.55	0.151±0.001^††	1.01±0.001^††	14.14±0.039^††	79.93±0.38
Gelrite 0.5%	147.10	0.139±0.001^††	0.92±0.003^††	13.03±0.055^††	78.92±0.47
SCMC 2.5%	167.80	0.092±0.001^††	0.61±0.003^††	8.75±0.195^††	76.68±1.82
XG 1.5%	180.28	0.071±0.001	0.48±0.002	6.79±0.050	77.53±0.47

Values are mean ± SE of 3 solutions viscosity in each group.
^†Statistically significant difference at 𝑃<0.05; ^††statistically significant difference at 𝑃<0.01; ^†††statistically significant difference at 𝑃<0.001 from control (voriconazole-HP-β-CD based solutions 1.5%, pH 7.0) as determined by one-way ANOVA followed by Dunnett’s test.